Antiretroviral activity of two polyisoprenylated acylphloroglucinols, 7-epi-nemorosone and plukenetione A, isolated from Caribbean propolis

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 10, 2010, Pages 670-677

  Diaz Carballo D ^a   Ueberla, K ^b   Kleff, V ^c   Ergun, S ^c   Malak, S ^c   Freistuehler, M ^d   Somogyi, S ^e   Kucherer C ^e   Bardenheuer, W ^a   Strumberg, D ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e ROBERT KOCH INSTITUTE   (Germany)

Author keywords

7 epi nemorosone; HIV; Plukenetione A; Polyisoprenylated acylphloroglucinols; Propolis; Reverse transcriptase

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 7 EPI NEMOROSONE; ADAMANTANE; ANTIRETROVIRUS AGENT; LENTIVIRUS VECTOR; PHLOROGLUCINOL DERIVATIVE; PLUKENETIONE A; PROTEIN KINASE B; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANTIVIRAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL STRAIN HEK293; CENTRAL AMERICA; CLUSIA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG ISOLATION; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; IN VITRO STUDY; ISOPRENYLATION; LENTIVIRINAE; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SIGNAL TRANSDUCTION; SIMIAN IMMUNODEFICIENCY VIRUS; STRUCTURE ANALYSIS;

EID: 77957652888     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48670     Document Type: Article

References (44)

1. Adachi S et al. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus. Scand J Gastroenterol. 2008; 43: 849-856. (Pubitemid 351918521)
2. Ahmad NM et al. Synthesis of polyprenylated acylphloroglucinols using bridgehead lithiation: the total synthesis of racemic clusianone and a formal synthesis of racemic garsubellin A. J Org Chem. 2007; 72: 4803-4815.
3. Alexaki A et al. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res. 2008; 6: 388-400.
4. Bernstein A. AIDS and the next 25 years. Science. 2008; 320: 717.
5. Bogenberger JM, Laybourn PJ. Human T lymphotropic virus Type 1 protein tax reduces histone levels. retrovirology. 2008; 5: 9.
6. Borgatti P et al. Extracellular HIV-1 Tat protein activates phosphatidylinositol 3- and Akt/PKB kinases in CD4+ T lymphoblastoid Jurkat cells. Eur J Immunol. 1997; 27: 2805-2811. (Pubitemid 27478347)
7. Chugh P et al. Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology. 2008; 5: 11.
8. Chugh P et al. Infection of human immunodeficiency virus and intracellular viral Tat protein exert a pro-survival effect in a human microglial cell line. J Mol Biol. 2007; 366: 67-81.
9. Chun TW et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis. 2008; 197: 714-720.
10. Churchill MJ et al. c-Myb influences HIV type 1 gene expression and virus production. AIDS Res Hum Retroviruses. 2001; 17: 1481-1488. (Pubitemid 33116751)
11. Churchill MJ et al. Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source. J Virol. 2006; 80: 1047-1052.
12. Cohen MS, Kashuba AD. Antiretroviral therapy for prevention of HIVinfection: new clues from an animal model. PLoS Med. 2008; 5: 30.
13. Coleman MP et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008; 9: 730-756.
14. Croce F et al. HIV/AIDS: epidemic update, new treatment strategies and impact on autoimmunity. Clin Exp Rheumatol. 2008; 26 (Suppl): 48-52.
15. Cuesta-Rubio O et al. Polyisoprenylated benzophenones in cuban propolis; biological activity of nemorosone. Z Naturforsch [C]. 2002; 57: 372-378.
16. Dasgupta P et al. Myb protein binds to human immunodeficiency virus 1 long terminal repeat (LTR) sequences and transactivates LTR-mediated transcription. Proc Natl Acad Sci U S A. 1990; 87: 8090-8094. (Pubitemid 20351659)
17. Diaz-Carballo D et al. The contribution of plukenetione A to the anti-tumoral activity of Cuban propolis. Bioorg Med Chem. 2008; 16: 9635-9643.
18. Diaz-Carballo Det al. Cytotoxic activity of nemorosone in neuroblastoma cells. J Cell Mol Med. 2008; 12: 2598-2608.
19. Diaz-Carballo D et al. Nemorosone blocks proliferation and induces apoptosis in leukemia cells. Int J Clin Pharmacol Ther. 2008; 4: 428-439.
20. Eilers M et al. MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells. Exp Biol Med (Maywood). 2008; 233: 1149-1160.
21. Elion R et al. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naive patients treated with ritonavir- boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily. HIV Clin Trials. 2008; 9: 213-224.
22. Fauci AS. 25 years of HIV. Nature. 2008; 453: 289-290.
23. Greene WC et al. Novel targets for HIV therapy. Antiviral Res. 2008; 80: 251-265.
24. Huerta-Reyes M et al. HIV-1 inhibition by extracts of Clusiaceae species from Mexico. Biol Pharm Bull. 2004; 27: 916-920.
25. Jorajuria S, Dereuddre-Bosquet N, Becher F et al. ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther. 2004; 9: 519-528.
26. Lebbe C. Humans herpesvirus 8 (HHV-8) and Kaposi sarcoma. Hautarzt. 2008; 59: 18-25.
27. Marcello A. Latency: the hidden HIV-1 challenge. Retrovirology. 2006; 3: 7.
28. Marsden MD, Zack JA. Eradication of HIV: current challenges and new directions. J Antimicrob Chemother. 2009; 63: 7-10.
29. Means RE, Greenough T, Desrosiers RC. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J Virol. 1997; 71: 7895-7902. (Pubitemid 27391740)
30. Peralta G et al. P-glycoprotein and human immunodeficiency virus infection. Enferm Infecc Microbiol Clin. 2008; 26: 150-159. (Pubitemid 351416488)
31. Piccinelli A et al. Structural revision of clusianone and 7-epi-clusianone and anti-HIV activity of polyisoprenylated benzophenones. Tetrahedron. 2005; 61: 8206-8211. (Pubitemid 41019142)
32. Quinn TC. HIV epidemiology and the effects of antiviral therapy on long-term consequences. Aids. 2008; 22 (Suppl): 7-12.
33. Rey J et al. Detection of different clonal EBV strains in Hodgkin lymphoma and nasopharyngeal carcinoma tissues from the same patient. Br J Haematol. 2008; 142: 79-81. (Pubitemid 351783158)
34. Roca B. Pharmacogenomics of antiretrovirals. Recent Pat Antiinfect Drug Discov. 2008; 3: 132-135.
35. Savarino A, Lucia MB, Rastrelli E et al. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndr. 2004; 35: 223-232.
36. Shen L, Siliciano RF. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol. 2008; 122: 22-28.
37. Steinstraesser L et al. Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptides. Retrovirology. 2005; 2: 2.
38. Suffredini IB et al. Antibacterial and cytotoxic activity of Brazilian plant extracts - Clusiaceae. Mem Inst Oswaldo Cruz. 2006; 101: 287-290. (Pubitemid 43962015)
39. Takagi R et al. Construction of the adamantane core of plukenetione-type polycyclic polyprenylated acylphloroglucinols. J Org Chem. 2008; 73: 9320-9325.
40. Telenti A, Zanger UM. Pharmacogenetics of anti- HIV drugs. Annu Rev Pharmacol Toxicol. 2008; 48: 227-256.
41. Tsukano C et al. Differentiation of nonconventional " carbanions"-the total synthesis of nemorosone and clusianone. Angew Chem Int Ed Engl. 2007; 46: 8840-8844.
42. Uberla K. Efficacy of AIDS vaccine strategies in nonhuman primates. Med Microbiol Immunol. 2005; 194: 201-206.
43. Uberla K. HIV vaccine development in the aftermath of the STEPstudy: re-focus on occult HIVinfection? PLoS Pathog. 2008; 4: 1000114.
44. Uberla K et al. Therapeutic immunization with Modified Vaccinia Virus Ankara (MVA) vaccines in SIV-infected rhesus monkeys undergoing antiretroviral therapy. J Med Primatol. 2007; 36: 2-9.